[{"data":1,"prerenderedAt":178},["ShallowReactive",2],{"drug-zanamivir":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":74,"warnings":84,"renal":92,"monitoring":93,"interactions":94,"review":95,"examples":98,"atc":107,"iran":109,"usApproval":121,"links":127,"populations":144},"zanamivir",1,{"fa":7,"en":8},"زانامیویر","Zanamivir","anti-infectives",{"fa":11,"en":12},"مهارکننده نورآمینیداز استنشاقی","Inhaled neuraminidase inhibitor",[14],{"name":15,"market":16},"Relenza","US",[18,19,7],"relenza","رلنزا",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"diskhaler","inhaler","inhaled","5 mg per blister (Diskhaler); dose = 2 inhalations",{"amount":27,"unit":28,"perUnit":29},5,"mg","actuation",[16],[32],{"source":33,"section":34},"fda-relenza","3",[36,54],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":50,"durationDays":53},"tx","influenza",{"fa":40,"en":41},"درمان آنفلوانزا (۷ سال به بالا) — ۱۰ mg (۲ استنشاق) دو بار در روز، ۵ روز","Influenza treatment (≥7 y) — 10 mg (2 inhalations) twice daily for 5 days",{"minAge":43},{"value":44,"unit":45},7,"year","fixed",{"perDose":48,"dosesPerDay":49},10,2,[51],{"source":33,"section":52},"2.2",{"min":27,"max":27},{"id":55,"disease":56,"label":57,"population":60,"type":46,"unit":28,"dose":62,"refs":63,"durationDays":66,"notes":67},"proph","influenza-prophylaxis",{"fa":58,"en":59},"پیشگیری خانگی (۵ سال به بالا) — ۱۰ mg یک بار در روز، ۱۰ روز","Household prophylaxis (≥5 y) — 10 mg once daily for 10 days",{"minAge":61},{"value":27,"unit":45},{"perDose":48,"dosesPerDay":5},[64],{"source":33,"section":65},"2.3",{"min":48,"max":48},[68],{"text":69,"refs":72},{"fa":70,"en":71},"همه‌گیری جامعه (بزرگسال و نوجوان): ۱۰ mg روزانه ۲۸ روز.","Community outbreaks (adults and adolescents): 10 mg daily for 28 days.",[73],{"source":33,"section":65},[75],{"id":76,"severity":77,"text":78,"refs":81},"ci","block",{"fa":79,"en":80},"سابقه آلرژی به اجزای فرآورده از جمله پروتئین شیر.","History of allergy to any ingredient, including milk proteins.",[82],{"source":33,"section":83},"4",[85],{"text":86,"refs":89},{"fa":87,"en":88},"برونکواسپاسم (گاه کشنده) — در آسم یا COPD توصیه نمی‌شود.","Bronchospasm (sometimes fatal) — not recommended in asthma or COPD.",[90],{"source":33,"section":91},"5",[],[],[],{"status":96,"reviewer":97,"date":97},"unverified",null,[99,104],{"regimen":37,"formulation":22,"input":100,"expect":103},{"ageYears":101,"weightKg":102},30,70,{"perDose":48,"tabletsPerDoseRounded":49},{"regimen":55,"formulation":22,"input":105,"expect":106},{"ageYears":101,"weightKg":102},{"perDose":48,"tabletsPerDoseRounded":49},[108],"J05AH01",{"status":110,"forms":111,"refs":116},"registered",[112],{"code":113,"en":114,"fa":115},"10015","ZANAMIVIR 5MG POWDER FOR INHALATION","پودر زانامیویر ۵ میلی‌گرم",[117],{"source":118,"section":119,"url":120},"darooyab-generic","G-1215\u002FZanamivir","https:\u002F\u002Fwww.darooyab.ir\u002FG-1215\u002FZanamivir",{"kind":122,"refs":123,"id":126},"NDA",[124],{"source":33,"section":125},"SPL approval \u002F marketing category","NDA021036",[128,131,135,139,142],{"kind":129,"url":130,"label":126},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021036",{"kind":132,"url":133,"label":134},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d7c3bcc3-0c0d-4068-fd80-88cf54a376ef","FDA Relenza",{"kind":136,"url":137,"label":138},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa699021.html","Zanamivir Oral Inhalation",{"kind":140,"url":141,"label":108},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AH01",{"kind":143,"url":120,"label":8},"darooyab",{"pregnancy":145,"lactation":154,"pediatric":162,"geriatric":170},{"level":146,"text":147,"quote":150,"refs":151},"caution",{"fa":148,"en":149},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data from published studies suggest that use of RELENZA during pregnancy is not associated with an increased risk of birth defects or adverse maternal or fetal outcomes.",[152],{"source":33,"section":153},"8.1",{"level":146,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of zanamivir in human milk or the effects on milk production.",[160],{"source":33,"section":161},"8.2",{"level":146,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Treatment of Influenza Safety and effectiveness of RELENZA for treatment of influenza have not been assessed in pediatric patients younger than 7 years, but were studied in a Phase 3 treatment trial in pediatric subjects, where 471 children aged 5 to 12 years received zanamivir or placebo [see Clinical Studies ( 14.1 …",[168],{"source":33,"section":169},"8.4",{"level":146,"text":171,"quote":174,"refs":175},{"fa":172,"en":173},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of subjects in 6 clinical trials of RELENZA for treatment of influenza, 59 subjects were aged 65 years and older, while 24 subjects were aged 75 years and older.",[176],{"source":33,"section":177},"8.5",1792191573579]